참고문헌 (34)

1. 1 Park DH Xu HD Shim J Li YC Lee JH Cho SC Han SS Lee YL Lee MJ Kwon SW Stephania delavayi Diels. Inhibits breast carcinoma proliferation through the p38MAPK/ NF-κB/COX-2 pathway Oncol Rep 26 833 841 2011 21725607 

2. 2 Baba M Ono M NF-κB activity inhibitor US Patent 6123943 Filed March 10, 1998; issued September 26, 2000 

3. 3 Nawawi A Nakamura N Meselhy MR Hattori M Kurokawa M Shiraki K Kashiwaba N Ono M In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1 Phytother Res 15 497 500 2001 10.1002/ptr.881 11536378 

   상세보기

4. 4 Ohsaki M Kurokawa M Nawawi A Nakamura N Hattori M Shiraki K Characterization of anti-herpes simplex virus type 1 activity of an alkaloid FK-3000 from Stephania cepharantha J Trad Med 19 129 136 2002 

5. 5 Ma C-M Nakamura N Miyashiro H Hattori M Komatsu K Kawahata T Otake T Screening of Chinese and Mongolian herbal drugs for anti-human immunodeficiency virus type 1 (HIV-1) activity Phytother Res 16 186 189 2002 10.1002/ptr.922 11933126 

   상세보기

6. 6 Masaki T Shiratori Y Rengifo W Igarashi K Matsumoto K Nishioka M Hatanaka Y Omata M Hepatocellular carcinoma cell cycle: study of Long-Evans Cinnamon rats Hepatology 32 711 720 2000 10.1053/jhep.2000.17705 11003614 

   상세보기

7. 7 Park DH Shin JW Park SK Seo JN Li L Jang JJ Lee MJ Diethylnitrosamine (DEN) induces irreversible hepatocellular carcinogenesis through overexpression of G1/S-phase regulatory proteins in rat Toxicol Lett 191 321 326 2009 10.1016/j.toxlet.2009.09.016 19822196 

   상세보기

8. 8 Masaki T Shiratori Y Rengifo W Igarashhi K Yamagata M Kurokohchi K Uchida N Miyauchi Y Yoshiji H Watanabe S Omata M Kuriyama S Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis Hepatology 37 534 543 2003 10.1053/jhep.2003.50112 12601350 

   상세보기

9. 9 Bana E Sibille E Valente S Cerella C Chaimbault P Kirsch G Dicato M Diederich M Bagrel D A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death Mol Carcinog 10 24 2013 (Epub ahead of print) 10.1002/mc.22094 24155226 

   상세보기

10. 10 Falco MD Luca AD Cell cycle as a target of antineoplastic drugs Curr Pharm Des 16 1417 1426 2010 10.2174/138161210791033914 20166983 

    상세보기

11. 11 Nilsson I Hoffmann I Cell cycle regulation by the cdc25 phosphatase family Prog Cell Cycle Res 4 107 114 2000 10.1007/978-1-4615-4253-7_10 10740819 

    상세보기

12. 12 Boutros R Dozier C Ducommun B The When and where of CDC25 phosphatase Curr Opin Cell Biol 18 185 191 2006 10.1016/j.ceb.2006.02.003 16488126 

    상세보기

13. 13 Norbury C Blow Nurse P Regulatory phosphorylation of the p34 cdc2 protein kinase in vertebrates EMBO J 10 3321 3329 1991 453058 --> 1655417 

    상세보기

14. 14 Lavecchia A Di Giovanni C Novellino E Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review Expert Opin Ther Pat 20 405 425 2010 10.1517/13543771003623232 20166845 

    상세보기

15. 15 Brezak MC Quaranta M Mondésert O Galacera MO Lavergne O Alby F Cazales M Baldin V Thurieau C Harnett J Lanco C Kasprzyk PG Prevost GP Ducommun B A novel synthetic inhibitor of CDC25 phosphastases: BN82002 Cancer Res 64 3320 3325 2004 10.1158/0008-5472.CAN-03-3984 15126376 

    상세보기

16. 16 Deep G Singh RP Agarwal C Kroll DJ Agarwal R Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin Oncogene 25 1053 1069 2006 10.1038/sj.onc.1209146 16205633 

    상세보기

17. 17 Brisson M Nguyen T Vogt A Yalowich J Giorgianni A Tobi D Bahar I Stephenson CRJ Wipf P Lazo JS Discovery and Characterization of novel small molecule inhibitors of human cdc25B dual specificity phosphatase Mol Pharmacol 66 824 833 2004 10.1124/mol.104.001784 15231869 

    상세보기

18. 18 Brezak MC Quaranta M Contour-Galcera MO Lavergne O Mondesert O Auvray P Kasprzyk PG Prevost GP Ducommun B Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases Mol Cancer Ther 4 1378 1387 2005 10.1158/1535-7163.MCT-05-0168 16170030 

    상세보기

19. 19 Brezak MC Valette A Quaranta M Contour-Galcera MO Jullien D Lavergne O Frongia C Bigg D Kasprzyk PG Prevost GP Ducommun B IRC-083864, a novel bis quinine inhibitor of CDC25 phosphatases active against human cancer cells Int J Cancer 124 1449 1456 2009 10.1002/ijc.24080 19065668 

    상세보기

20. 20 Mikhailov A Shinohara M Rieder C The p38-mediated stress-activated checkpoint Cell Cycle 4 57 62 2005 10.4161/cc.4.1.1357 15611649 

    상세보기

21. 21 Hirose Y Katayama M Mirzoeva OK Berger MS Pieper RO Akt activation suppresses chk2-mediated, methylating agent-induced G2 arrest and protects from Temozolomide-induced mitotic catastrophe and cellular senescence Cancer Res 65 4861 4869 2005 10.1158/0008-5472.CAN-04-2633 15930307 

    상세보기

22. 22 Kashiwaba N Morooka S Kimura M Ono M Toda J Suzuki H Sano T New morphinane and hasubanane alkaloids form Stephania cepharantha J Nat Prod 59 476 480 1996 10.1021/np960080d 

    상세보기

23. 23 Boutros R Lobjois V Ducommun B CDC25 phosphastases in cancer cells: key players? Good targets? Nature 7 495 507 2007 

24. 24 Wood CD Thornton TM Sabio G Davis RA Rincon M Nuclear localization of p38MAPK in response to DNA damage Int J Biol Sci 5 428 437 2009 10.7150/ijbs.5.428 2702826 --> 19564926 

    상세보기

25. 25 Underwood DC Osborn RR Koitzer CJ Adams JL Lee JC Webb EF Carpenter DC Bochnowicz S Thomas HC Hay DW Griswold DE SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence J Pharmacol Exp Ther 293 281 288 2000 10734180 

    상세보기

26. 26 O’Farrell PH Triggering the all-or-nothing switch into mitosis Trends Cell Biol 11 512 519 2001 10.1016/S0962-8924(01)02142-0 11719058 

    상세보기

27. 27 Kim KR Kwon JL Kim JS No Z Kim HR Cheon HG EK-6136 (3-methyl-4-(O-methyl-oximino)-1-phenylpyrazolin-5-one): a novel Cdc25B inhibitor with antiproliferative activity Eur J Pharmacol 528 37 42 2005 10.1016/j.ejphar.2005.10.027 16324698 

    상세보기

28. 28 Sherr CJ Roberts JM CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 13 1501 1512 1997 10.1101/gad.13.12.1501 10385618 

    상세보기

29. 29 LaBaer J Garrett MD Stevenson LF Slingerland JM Sandhu C Chou HS Fattaey A Harlow E New functional activities for the p21 family of CDK inhibitors Genes Dev 11 847 862 1997 10.1101/gad.11.7.847 9106657 

    상세보기

30. 30 Cheng M Olivier P Diehl JA Fero M Roussel MF Foberts JM Sherr CJ The p21(CIP1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin-D-dependent kinases in murine fibroblasts EMBO J 18 1571 1583 1999 10.1093/emboj/18.6.1571 1171245 --> 10075928 

    상세보기

31. 31 http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1271 . 

32. 32 Senderowicz AM Sausville EA Preclinical and clinical development of cyclin-dependent kinase modulators J Natl Cancer Inst 92 376 387 2000 10.1093/jnci/92.5.376 10699068 

    상세보기

33. 33 http://dtp.nci.nih.gov/timeline/flash/success_stories/s12_flavopiridol.htm . 

34. 34 Jones CB Clements MK Wasi S Daoud SS Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest Cancer Chemother Pharmacol 45 252 258 2000 10.1007/s002800050037 10663644 

    상세보기